Vimugen Completes RMB 300 Million Series D Financing Led by Sequoia China, Advances Ophthalmic Drug Pipeline Including VVN001 Phase II Trial in the U.S.

VCBeat (WeChat ID: vcbeat) has learned that VIVAVISION Biotechnology (Shanghai) Co., Ltd. (“VIVAVISION”), a leading Chinese innovative ophthalmic pharmaceutical company, has announced the completion of its RMB 300 million Series D financing. The funds will be used to support the clinical development of multiple innovative ophthalmic drug products, including the ongoing Phase II clinical trial of VVN001 for dry eye disease in the United States.

This round of financing was led by HongShan, with participation from Cenova Capital, GTJA Investment Group, FengHe Fund Management, SPINNOTEC, CICC Strategic Investment, and Tibet Ruihai, among others. Existing shareholders JMCR, Changrong Capital, and Beta Industrial Fund continued to increase their investments.

Dr. Shen Wang, Founder and Chairman of VIVAVISIONstated: “We sincerely appreciate the continued trust and support from our investment partners. With the joint efforts of all shareholders and the management team, VIVAVISION will strive to provide safer and more effective innovative therapies for ophthalmic patients worldwide as soon as possible.”

Dr. Cui Ping Gu, Managing Director at HongShan“HongShan has consistently focused on unmet needs in the ophthalmology sector. We are impressed by VIVAVISION’s exceptional expertise and insights in ophthalmic drug development. We have confidence in Dr. Shen Wang and look forward to his leadership in growing the company into a world-class innovative ophthalmic pharmaceutical enterprise.”

VIVAVISION is a clinical-stage innovative pharmaceutical company focused on the field of ophthalmic therapeutics. Founded by an international team of top-tier experts in ophthalmic drug development, the company has established a unique platform for R&D of innovative ophthalmic drugs. Multiple independently developed innovative drug candidates have already entered or are poised to enter clinical trials.

HongShan has always been committed to helping entrepreneurs build enduring, great companies by providing its portfolio companies with abundant global resources and valuable historical experience. Over the past 49 years, HongShan has invested in numerous innovative enterprises and leaders shaping industry trends. As the “entrepreneur behind entrepreneurs,” HongShan China focuses on investment opportunities in three key sectors: TMT (Technology, Media, and Telecom), healthcare, and consumer goods/services. Over the past 16 years, HongShan China has invested in nearly 600 companies characterized by distinct technological advantages, innovative business models, and high growth potential.